Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CDXCNASDAQ:FOMXNASDAQ:MNMDNYSE:USNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCDXCChromaDex$6.16$2.31▼$9.18$611.50M2.21813,359 shs554,788 shsFOMXMenlo Therapeutics$2.99$2.99$1.97▼$4.84$184.12M1.66518,350 shsN/AMNMDMind Medicine (MindMed)$7.17-1.8%$6.60$4.70▼$10.44$541.72M2.521.36 million shs985,843 shsUSNAUSANA Health Sciences$29.60-0.6%$28.04$23.10▼$48.85$554.59M0.63136,161 shs171,587 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCDXCChromaDex0.00%0.00%0.00%+0.32%+159.57%FOMXMenlo Therapeutics0.00%0.00%0.00%0.00%0.00%MNMDMind Medicine (MindMed)-1.78%-7.96%+9.63%+12.91%-8.66%USNAUSANA Health Sciences-0.50%+0.90%+1.37%+1.95%-35.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCDXCChromaDex2.5915 of 5 stars3.50.00.04.00.60.01.9FOMXMenlo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)1.9189 of 5 stars3.60.00.00.03.40.80.6USNAUSANA Health Sciences4.0036 of 5 stars2.01.00.03.21.41.74.4Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCDXCChromaDex 3.00Buy$9.03∞ UpsideFOMXMenlo Therapeutics 0.00N/AN/AN/AMNMDMind Medicine (MindMed) 3.27Buy$25.50255.65% UpsideUSNAUSANA Health Sciences 2.00Hold$36.0021.62% UpsideCurrent Analyst Ratings BreakdownLatest FOMX, CDXC, MNMD, and USNA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025MNMDMind Medicine (MindMed)Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025MNMDMind Medicine (MindMed)Chardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/17/2025CDXCChromaDexHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00(Data available from 6/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCDXCChromaDex$99.60M0.00N/AN/A$0.38 per share0.00FOMXMenlo Therapeutics$3.60M51.15N/AN/A$1.70 per share1.76MNMDMind Medicine (MindMed)N/AN/AN/AN/A$1.90 per shareN/AUSNAUSANA Health Sciences$876.24M0.63$4.06 per share7.29$25.99 per share1.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCDXCChromaDex-$4.94M$0.10787.290.00N/A1.62%4.85%2.70%N/AFOMXMenlo Therapeutics-$74.16M-$1.70N/AN/AN/AN/A-100.58%-81.39%N/AMNMDMind Medicine (MindMed)-$95.73M-$1.29N/AN/AN/AN/A-47.56%-35.55%8/12/2025 (Estimated)USNAUSANA Health Sciences$63.79M$1.8210.4610.240.936.30%10.64%8.48%7/22/2025 (Estimated)Latest FOMX, CDXC, MNMD, and USNA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025MNMDMind Medicine (MindMed)-$0.36-$0.35+$0.01-$0.35N/AN/A4/22/2025Q1 2025USNAUSANA Health Sciences$0.70$0.73+$0.03$0.49$243.08 million$249.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCDXCChromaDexN/AN/AN/AN/AN/AFOMXMenlo TherapeuticsN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/AUSNAUSANA Health SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCDXCChromaDexN/A2.952.35FOMXMenlo Therapeutics0.245.725.72MNMDMind Medicine (MindMed)0.099.009.00USNAUSANA Health SciencesN/A3.933.37Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCDXCChromaDex15.41%FOMXMenlo Therapeutics46.46%MNMDMind Medicine (MindMed)27.91%USNAUSANA Health Sciences54.25%Insider OwnershipCompanyInsider OwnershipCDXCChromaDex9.64%FOMXMenlo Therapeutics2.95%MNMDMind Medicine (MindMed)2.45%USNAUSANA Health Sciences0.63%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCDXCChromaDex12077.75 million69.02 millionOptionableFOMXMenlo Therapeutics8061.58 millionN/AOptionableMNMDMind Medicine (MindMed)4075.55 million71.68 millionOptionableUSNAUSANA Health Sciences1,90018.62 million19.00 millionOptionableFOMX, CDXC, MNMD, and USNA HeadlinesRecent News About These CompaniesUSANA Takes Home Five Best of State Awards, Including the Coveted Best of State StatueJune 12 at 7:07 AM | prnewswire.comUSANA Health Sciences, Inc. (NYSE:USNA) Director Sells $14,830.00 in StockJune 10, 2025 | marketbeat.comMillennium Management LLC Makes New Investment in USANA Health Sciences, Inc. (NYSE:USNA)June 8, 2025 | marketbeat.comReflecting On Personal Care Stocks’ Q1 Earnings: USANA (NYSE:USNA)June 4, 2025 | msn.comUSANA Executive Chairman Kevin Guest Celebrates National Outdoors Month with a Call to ...June 2, 2025 | gurufocus.comUSANA Executive Chairman Kevin Guest Celebrates National Outdoors Month with a Call to Reconnect with NatureJune 2, 2025 | prnewswire.comUSANA Health Sciences, Inc. (NYSE:USNA) COO Walter Noot Sells 6,291 SharesMay 30, 2025 | marketbeat.comAmeriprise Financial Inc. Has $2.75 Million Stock Position in USANA Health Sciences, Inc. (NYSE:USNA)May 30, 2025 | marketbeat.comUSANA Health Sciences (NYSE:USNA) Upgraded at Wall Street ZenMay 24, 2025 | marketbeat.comNorthern Trust Corp Acquires 19,266 Shares of USANA Health Sciences, Inc. (NYSE:USNA)May 24, 2025 | marketbeat.comUSANA Health Sciences, Inc. (NYSE:USNA) Shares Bought by Jane Street Group LLCMay 22, 2025 | marketbeat.comShareholders in USANA Health Sciences (NYSE:USNA) are in the red if they invested five years agoMay 21, 2025 | finance.yahoo.comUSANA Health Sciences, Inc. (NYSE:USNA) Shares Bought by Jacobs Levy Equity Management Inc.May 17, 2025 | marketbeat.comInsider Selling: USANA Health Sciences, Inc. (NYSE:USNA) CFO Sells 4,548 Shares of StockMay 14, 2025 | marketbeat.comUSANA Health Sciences, Inc. (NYSE:USNA) CFO Sells $134,666.28 in StockMay 13, 2025 | insidertrades.comUSNA Q1 Earnings Call: Product Expansion and Market Momentum Drive OutperformanceMay 13, 2025 | finance.yahoo.comUSANA Releases 2024 Sustainability ReportMay 8, 2025 | prnewswire.comKevin Guest Shares Transformative Success Strategies on Executive Coaching Day, May 1May 1, 2025 | prnewswire.comUSANA Celavive Postbiotic Rescue Serum Selected as a Good Housekeeping 2025 Beauty Award WinnerApril 28, 2025 | prnewswire.comUsana Health Sciences Inc (USNA) Q1 2025 Earnings Call Highlights: Strong Sales Growth and ...April 24, 2025 | finance.yahoo.comUSANA Health Sciences Sees Sales Growth Amid Earnings DeclineApril 24, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFOMX, CDXC, MNMD, and USNA Company DescriptionsChromaDex NASDAQ:CDXCChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.Menlo Therapeutics NASDAQ:FOMXFoamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.Mind Medicine (MindMed) NASDAQ:MNMD$7.17 -0.13 (-1.78%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$7.10 -0.07 (-0.98%) As of 06/13/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.USANA Health Sciences NYSE:USNA$29.60 -0.18 (-0.60%) Closing price 06/13/2025 03:59 PM EasternExtended Trading$29.54 -0.05 (-0.19%) As of 06/13/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products. It also provides Celavive, a skin care regimen for various skin care types and ethnicities; and other products for prenatal, infant, and young child age groups. In addition, the company offers materials and online tools to assist associates in building their businesses, as well as in marketing products. It offers its products through retail stores and online. The company has a research collaboration agreement with Beijing University of Chinese Medicine; and National Sports Training Bureau. USANA Health Sciences, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
